Factory Ubonelelo ngokuthe ngqo 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2

Sihlala sicinga kwaye siziqhelanise nokutshintsha kwemeko yakho, kwaye sikhule.Sijolise ekufezekiseni ingqondo nomzimba otyebileyo kunye nokuphila kwiFactory Ukubonelela ngokuthe ngqo 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Injongo yethu iya kuba kukunceda abathengi bazi iinjongo zabo. .Besivelisa iinzame ezilungileyo zokuphumeza le ngxaki yokuwina-win kwaye siyakwamkela ngokunyanisekileyo ukuba ubhalisele thina.
Sihlala sicinga kwaye siziqhelanise nokutshintsha kwemeko yakho, kwaye sikhule.Sijonge ekufezekiseni ingqondo nomzimba otyebileyo kunye nokuphilaI-China 4-Dibuthylamino-2-Hydroxybenzophenone kunye ne-Bba, Ubukho bethu obuqhubekayo beemveliso zodidi oluphezulu kunye nezisombululo ngokudityaniswa nenkonzo yethu ebalaseleyo yokuthengisa kwangaphambili kunye nenkonzo yasemva kokuthengisa iqinisekisa ukhuphiswano olomeleleyo kwimakethi eyandayo yehlabathi.bamkele abathengi abatsha nabadala abavela kuzo zonke iindlela zobomi ukuba baqhagamshelane nathi kubudlelwane beshishini elizayo kunye nempumelelo efanayo!

I-2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid isetyenziswe njengendawo ephakathi kwe-Eltrombopag.
I-Eltrombopag, ephuhliswe yi-GlaxoSmithKline (GSK) e-UK kwaye kamva iphuhliswe ngokudibeneyo kunye ne-Novartis eSwitzerland, yeyokuqala kwaye ivunyiwe kuphela i-molecule encinci ye-non peptide TPO receptor agonist emhlabeni.I-Eltrombopag yavunywa yi-US FDA kwi-2008 yonyango lwe-idiopathic thrombocytopenic purpura (ITP), kunye ne-2014 yonyango lwe-anemia ye-aplastic enzima (AA).Ikwalichiza lokuqala elavunywa yi-US FDA kunyango lwe-AA kwiminyaka engama-30 yakutsha nje.
NgoDisemba 2012, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kwizigulane ezine-hepatitis C engapheliyo (CHC), ukwenzela ukuba izigulane ze-hepatitis C ezine-prognosis embi ngenxa yokubala kweplatelet ephantsi inokuqala kwaye igcine unyango oluqhelekileyo lwe-interferon kwizifo zesibindi.NgoFebruwari3, 2014, i-GlaxoSmithKline yabhengeza ukuba i-FDA inike isiqinisekiso sonyango lwe-Eltrombopag kunyango lwe-hemopenia kwizigulane ezine-chemicalbook aplastic anemia (SAA) ezinzima ezingazange ziphendule ngokupheleleyo kwi-immunotherapy.Ngo-Agasti 24, i-2015, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kubantu abadala kunye nabantwana abaneminyaka eyi-1 kunye nangaphezulu kunye ne-immune immune thrombocytopenia (ITP) abangenayo impendulo eyaneleyo kwi-corticosteroids, i-immunoglobulins okanye i-splenectomy.NgoJanuwari4, 2018, i-Eltrombopag yavunywa ukuba ibhalwe e-China kunyango lwe-immune immune thrombocytopenia (ITP).

Sihlala sicinga kwaye siziqhelanise nokutshintsha kwemeko yakho, kwaye sikhule.Sijolise ekufezekiseni ingqondo nomzimba otyebileyo kunye nokuphila kwiFactory Ukubonelela ngokuthe ngqo 4-Dibuthylamino-2-Hydroxybenzophenone-2-Carboxylic Acid (BBA) CAS 54574-82-2, Injongo yethu iya kuba kukunceda abathengi bazi iinjongo zabo. .Besivelisa iinzame ezilungileyo zokuphumeza le ngxaki yokuwina-win kwaye siyakwamkela ngokunyanisekileyo ukuba ubhalisele thina.
Factory Ubonelelo ngokuthe ngqoI-China 4-Dibuthylamino-2-Hydroxybenzophenone kunye ne-Bba, Ubukho bethu obuqhubekayo beemveliso zodidi oluphezulu kunye nezisombululo ngokudityaniswa nenkonzo yethu ebalaseleyo yokuthengisa kwangaphambili kunye nenkonzo yasemva kokuthengisa iqinisekisa ukhuphiswano olomeleleyo kwimakethi eyandayo yehlabathi.bamkele abathengi abatsha nabadala abavela kuzo zonke iindlela zobomi ukuba baqhagamshelane nathi kubudlelwane beshishini elizayo kunye nempumelelo efanayo!